Health care reform, the patient-centered medical home, and the impact of environmental change on global health are just a few of the topics to be discussed at the Internal Medicine 2009 Medicine 2009 in Philadelphia this week.
Senate GOP leadership released a revised version of its healthcare bill, upping opioid crisis capital, among other changes, but Medicaid funding is still due to be cut.
Patients with resected brain metastases who underwent stereotactic radiosurgery had lower rates of local recurrence compared with observation alone, according to the results of a phase III trial.
The FDA has expanded the approval of blinatumomab (Blincyto) for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia in adults and children.
T-DM1 administered for 12 weeks with or without endocrine therapy yields good rates of pathologic complete response in women with HER2-positive/hormone receptor–positive breast cancer, according to a new randomized trial.
Treatment of advanced melanoma with the checkpoint inhibitor nivolumab beyond RECIST-defined progression resulted in clinical benefit for selected patients, according to pooled, retrospective data from two phase III trials.
Long-term follow-up found no significant differences in all-cause or disease-related mortality in men with early prostate cancer randomized to either radical prostatectomy or to observation. Surgery led to more adverse events, but less treatment for disease progression.
Use of the EGFR inhibitor cetuximab with chemoradiation did not improve survival in patients with esophageal carcinoma compared with chemoradiation alone, according to the results of the phase III RTOG 0436 trial.
Patients with high-risk diffuse large B-cell lymphoma had a reduced risk of treatment failure, but no survival improvement, with an abbreviated course of rituximab-dose-dense chemotherapy plus high-dose chemotherapy and transplant compared with a full course of chemotherapy.
This video examines the management of resectable pancreatic cancer, including how this type of disease is best defined, the latest standard of care in the adjuvant setting, and emerging trends in surveillance.
![Subscribe to No name on [sitename]](http://www.cancernetwork.com/misc/feed.png){kind=small}